Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ENDRA Life Sciences (NDRA) Gains from Investment Securities (2019 - 2021)

ENDRA Life Sciences (NDRA) has disclosed Gains from Investment Securities for 3 consecutive years, with $3.6 million as the latest value for Q3 2021.

  • Quarterly Gains from Investment Securities rose 880.38% to $3.6 million in Q3 2021 from the year-ago period, while the trailing twelve-month figure was $3.6 million through Sep 2021, up 6039.91% year-over-year, with the annual reading at $492352.0 for FY2025, 15.75% down from the prior year.
  • Gains from Investment Securities for Q3 2021 was $3.6 million at ENDRA Life Sciences, up from $331520.0 in the prior quarter.
  • The five-year high for Gains from Investment Securities was $3.6 million in Q3 2021, with the low at -$424210.0 in Q4 2019.
  • Average Gains from Investment Securities over 3 years is $432734.0, with a median of $158187.5 recorded in 2019.
  • The sharpest move saw Gains from Investment Securities skyrocketed 2504.18% in 2020, then fell 15.95% in 2021.
  • Over 3 years, Gains from Investment Securities stood at -$424210.0 in 2019, then rose by 14.17% to -$364113.0 in 2020, then soared by 1080.38% to $3.6 million in 2021.
  • According to Business Quant data, Gains from Investment Securities over the past three periods came in at $3.6 million, $331520.0, and -$364113.0 for Q3 2021, Q1 2021, and Q4 2020 respectively.